Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate

Blood

Volumn 110, Issue 6, 2007, Pages 2049-2056

  Dahle, Jostein ^a   Borrebæk, Jørgen ^b   Jonasdottir, Thora J ^c   Hjelmerud, Anne Kristine ^a   Melhus, Katrine B ^a   Bruland, Øyvind S ^d   Press, Oliver W ^e   Larsen, Roy H ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Algeta ASA   (Norway)

^c NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; IBRITUMOMAB TIUXETAN; RADIOISOTOPE; RITUXIMAB; THORIUM; THORIUM 227; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; IN VITRO STUDY; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RAJI CELL; TUMOR REGRESSION; TUMOR VOLUME;

EID: 34548829082     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-066803     Document Type: Article

References (30)

1. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
2. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351-2357.
3. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
4. Schilder R, Molina A, Bartlett N, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2004;19:478-481.
5. Gordon LI, Witzig T, Molina A, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma. 2004;5:98-101.
6. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
7. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des. 2000;6:1433-1455.
8. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540.
9. Miederer M, McDevitt MR, Borchardt P, et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res. 2004;10:6985-6992.
10. 223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451-4459.
11. 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. Anticancer Res. 2006;26:2841-2848.
12. Henriksen G, Hoff P, Larsen RH. Evaluation of potential chelating agents for radium. Appl Radiat Isot. 2002;56:667-671.
13. 227Th-labeled antibodies, assessment of serum stability and antigen binding ability. Cancer Biother Radiopharm. 2007;22:In press. DOI:10.4089/cbr.2006.321.
14. 227Th-DOTA-p-benzyl-rituximab to CD20-positive lymphoma cells. Cancer Biother Radiopharm. 2007;22:In press.
15. 211At- labeled antibodies for clinical use. J Nucl Med. 2001;42:1508-1515.
16. 227Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. Nucl Med Biol. 2006;33:271-279.
17. 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s-6257s.
18. 223Ra injected intravenously into mice: histology, clinical chemistry and hematology. In Vivo. 2006;20:325-331.
19. Henriksen G, Bruland OS, Larsen RH. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents. Anticancer Res. 2004;24:101-105.
20. Lindmo T, Bunn PA Jr. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol. 1986;121:678-91:678-691.
21. Landsverk KS, Lyng H, Stokke T. The response of malignant B lymphocytes to ionizing radiation: cell cycle arrest, apoptosis and protection against the cytotoxic effects of the mitotic inhibitor nocodazole. Radiat Res. 2004;162:405-415.
22. National Nuclear Data Center, http://www.nndc.bnl.gov, Brookhaven National Laboratory. 2007. Accessed July 17, 2007.
23. Yuan J. Estimation of variance for AUC in animal studies. J Pharm Sci. 1993;82:761-763.
24. Ashmore LM, Shopp GM, Edwards BS. Lymphocyte subset analysis by flow cytometry: comparison of three different staining techniques and effects of blood storage. J Immunol Methods. 1989;118:209-215.
25. Prescribing Information for Rituximab. http://www.rituximab.com/lymphoma/ HCP/index.jsp. IDEC Pharmaceuticals. 2006. Accessed July 17, 2007.
26. Aurlien E, Kvinnsland Y, Larsen RH, Bruland OS. Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro: comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation. Int J Radiat Biol. 2002;78:133-142.
27. Sawant SG, Randers-Pehrson G, Metting NF, Hall EJ. Adaptive response and the bystander effect induced by radiation in C3H 10T(1/2) cells in culture. Radiat Res. 2001;156:177-180.
28. Kvinnsland Y, Stokke T, Aurlien E. Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res. 2001;155:288-296.
29. Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature. 1977;266:653-655.
30. Ma D, McDevitt MR, Barendswaard E, et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia. 2002;16:60-66.